CD274 and cancer: Recently, immune checkpoint inhibitors (ICIs), including inhibitors of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and its ligand (PD-L1), have demonstrated durable clinical responses in several cancers [14,15,16].